+

WO2000066724A3 - Derives d'oligonucleotides diriges contre les arn messagershumains bcl-xl et bcl-2 - Google Patents

Derives d'oligonucleotides diriges contre les arn messagershumains bcl-xl et bcl-2 Download PDF

Info

Publication number
WO2000066724A3
WO2000066724A3 PCT/EP2000/003708 EP0003708W WO0066724A3 WO 2000066724 A3 WO2000066724 A3 WO 2000066724A3 EP 0003708 W EP0003708 W EP 0003708W WO 0066724 A3 WO0066724 A3 WO 0066724A3
Authority
WO
WIPO (PCT)
Prior art keywords
human bcl
oligonucleotide derivatives
mrna
directed against
bcl
Prior art date
Application number
PCT/EP2000/003708
Other languages
English (en)
Other versions
WO2000066724A2 (fr
Inventor
Uwe Zangemeister-Wittke
Gerd Luedke
Dieter Huesken
Original Assignee
Univ Zuerich
Zangemeister Wittke Uwe
Gerd Luedke
Dieter Huesken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich, Zangemeister Wittke Uwe, Gerd Luedke, Dieter Huesken filed Critical Univ Zuerich
Priority to EP00925239A priority Critical patent/EP1181361A2/fr
Priority to AU44025/00A priority patent/AU4402500A/en
Publication of WO2000066724A2 publication Critical patent/WO2000066724A2/fr
Publication of WO2000066724A3 publication Critical patent/WO2000066724A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention a trait à des dérivés d'oligonucléotide antisens dirigés contre l'ARN messager humain bcl-xL et capables de moduler la biosynthèse de la protéine humaine bcl-xL. Elle concerne, de surcroît, des dérivés d'oligonucléotide antisens dirigés à la fois contre l'ARN messager humain bcl-xL et l'ARN messager humain bcl-2 et capables de moduler la biosynthèse des deux protéines humaines bcl-xL et bcl-2. Elle porte également sur des compositions pharmaceutiques renfermant ces dérivés d'oligonucléotide, sur l'usage qui en est fait ainsi que sur des méthodes thérapeutiques et diagnostiques utilisant ces dérivés d'oligonucléotide.
PCT/EP2000/003708 1999-04-30 2000-04-26 Derives d'oligonucleotides diriges contre les arn messagershumains bcl-xl et bcl-2 WO2000066724A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00925239A EP1181361A2 (fr) 1999-04-30 2000-04-26 Derives d'oligonucleotides diriges contre les arn messagershumains bcl-xl et bcl-2
AU44025/00A AU4402500A (en) 1999-04-30 2000-04-26 Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9910119.8A GB9910119D0 (en) 1999-04-30 1999-04-30 Organic compounds
GB9910119.8 1999-04-30

Publications (2)

Publication Number Publication Date
WO2000066724A2 WO2000066724A2 (fr) 2000-11-09
WO2000066724A3 true WO2000066724A3 (fr) 2001-02-08

Family

ID=10852654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003708 WO2000066724A2 (fr) 1999-04-30 2000-04-26 Derives d'oligonucleotides diriges contre les arn messagershumains bcl-xl et bcl-2

Country Status (4)

Country Link
EP (1) EP1181361A2 (fr)
AU (1) AU4402500A (fr)
GB (1) GB9910119D0 (fr)
WO (1) WO2000066724A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
DE10258677A1 (de) * 2002-12-13 2004-06-24 Elez, Vera, Dr. Kombinations-antisense-Oligonukleotid-Krebstherapie
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
MX2016009753A (es) 2014-01-28 2017-07-07 Buck Inst For Res On Aging Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008350A1 (fr) * 1993-09-20 1995-03-30 Reed John C REGULATION DE L'EXPRESSION DU GENE bcl-2
WO1995031470A2 (fr) * 1994-05-13 1995-11-23 Merck Frosst Canada Inc. Inhibiteurs antisens de l'expression de genes
US5470974A (en) * 1985-03-15 1995-11-28 Neu-Gene Development Group Uncharged polynucleotide-binding polymers
WO1998018812A1 (fr) * 1996-10-25 1998-05-07 Hisamitsu Pharmaceutical Co., Inc. Oligomeres inhibant l'expression de genes de l'interleukine
WO2000001393A2 (fr) * 1998-07-02 2000-01-13 The Trustees Of Columbia University In The City Of New York OLIGONUCLEOTIDES INHIBITEURS DE bcl-xL
WO2000020432A1 (fr) * 1998-10-07 2000-04-13 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression du gene bcl-x

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470974A (en) * 1985-03-15 1995-11-28 Neu-Gene Development Group Uncharged polynucleotide-binding polymers
WO1995008350A1 (fr) * 1993-09-20 1995-03-30 Reed John C REGULATION DE L'EXPRESSION DU GENE bcl-2
WO1995031470A2 (fr) * 1994-05-13 1995-11-23 Merck Frosst Canada Inc. Inhibiteurs antisens de l'expression de genes
WO1998018812A1 (fr) * 1996-10-25 1998-05-07 Hisamitsu Pharmaceutical Co., Inc. Oligomeres inhibant l'expression de genes de l'interleukine
WO2000001393A2 (fr) * 1998-07-02 2000-01-13 The Trustees Of Columbia University In The City Of New York OLIGONUCLEOTIDES INHIBITEURS DE bcl-xL
WO2000020432A1 (fr) * 1998-10-07 2000-04-13 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression du gene bcl-x

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GAUTSCHI OLIVER ET AL: "Potent anti-tumor activity of a bcl-2/bcl-xL bispecific antisense oligonucleotide against solid tumors of diverse histological origin.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 642, XP000926075, ISSN: 0197-016X *
LEUDKE G H ET AL: "Antisense oligodeoxynucleotides designed to downregulates the expression of bcl-xL and of bcl-2 and bcl-xL simultaneously, restore the apoptotic response of lung cancer cell lines.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 39, March 1998 (1998-03-01), 89th Annual Meeting of the American Association for Cancer Research;New Orleans, Louisiana, USA; March 28-April 1, 1998, March, 1998, pages 417, XP000960954, ISSN: 0197-016X *
LUEDTKE G H ET AL: "Antisense oligonucleotides targeting sequences shared by the Bcl-2 and Bcl-xL efficiently downregulate expression of both proteins and induce apoptosis of lung cancer cells", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH,US,PHILADELPHIA, AACR, vol. 38, 1997, pages 170, XP002080870 *
OBIKA S ET AL: "Properties of Novel Oligonucleotide Analogues Containing an Acyclic Nucleoside and a Carbamate Linkage", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 6, no. 12, 18 June 1996 (1996-06-18), pages 1357 - 1360, XP004134840, ISSN: 0960-894X *
ZANGEMEISTER-WITTKE U ET AL: "Bcl-2 antisense oligodeoxynucleotide 2009 synergizes with chemotherapy on lung cancer cell lines and has antitumor activity against lung cancer xenografts.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 39, March 1998 (1998-03-01), 89th Annual Meeting of the American Association for Cancer Research;New Orleans, Louisiana, USA; March 28-April 1, 1998, March, 1998, pages 417, XP002153619, ISSN: 0197-016X *
ZANGEMEISTER-WITTKE U ET AL: "Novel approaches to the treatment of small-cell lung cancer.", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 55, no. 12, September 1999 (1999-09-01), pages 1585 - 1598, XP000960960, ISSN: 1420-682X *
ZANGEMEISTER-WITTKE U ET AL: "Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.", BRITISH JOURNAL OF CANCER, vol. 78, no. 8, October 1998 (1998-10-01), pages 1035 - 1042, XP000965123, ISSN: 0007-0920 *

Also Published As

Publication number Publication date
AU4402500A (en) 2000-11-17
GB9910119D0 (en) 1999-06-30
EP1181361A2 (fr) 2002-02-27
WO2000066724A2 (fr) 2000-11-09

Similar Documents

Publication Publication Date Title
WO2001026693A3 (fr) Production de conjugues d'agents therapeutiques de polyglutamate
EP2332955A3 (fr) Modulation antisens de l'expression d'acyl-coa cholesterol acyltransferase 2
AU2989900A (en) Microwave systems for medical hyperthermia, thermotherapy and diagnosis
HK1044545A1 (zh) 貝他分泌酶組合物及其方法
EP2221376A3 (fr) Modulation anti-sens d'expression soluble de superoxide dismutase 1
AU2208401A (en) Inhibitors of complement activation, their preparation and use
HK1032958A1 (en) Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments.
CA2368574A1 (fr) Compositions destinees a la prevention et au traitement de l'allergie de type i
WO2002026191A3 (fr) Procedes, compositions et dispositifs utilisant des cellules/capsules urticantes pour administrer un agent therapeutique ou cosmetique dans un tissu
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
MXPA02012249A (es) Peptidos, composiciones y metodos para el tratamiento de burkholderia cepacia.
AU2002226030A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
MXPA03009984A (es) PREPARACION PARA LA REMOCIoN DE MATERIAL QUERATINOSO ANORMAL.
AU2001282730A1 (en) Seal-oil-based pharmaceutical, cosmetic, dermo-cosmetic, hygiene, alimentary andpara-alimentary (food-supplements) products; their methods of preparation; thei r uses as preventive and/or as therapeutic agents
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
WO2000066724A3 (fr) Derives d'oligonucleotides diriges contre les arn messagershumains bcl-xl et bcl-2
AU5539798A (en) Sulfonamide-substituted chromans, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
AU6866500A (en) Chromone derivatives, process for the preparation of the same and uses thereof
HUP0200343A3 (en) Phenylalaninol derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203212A3 (en) Integrin inhibitors, process for preparation thereof, their use preparation of pharmaceutical compositions and the compositions
HUP0201810A3 (en) Sootepenseone and its derivatives, their preparation and use as medicament
AU2001240820A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
AU1564300A (en) NF-kB activation inhibitors, and their pharmaceutical uses
WO2002036105A3 (fr) Utilisation d'agents sequestrants de cortisol dans le cadre du traitement de troubles lies a l'hypercortisolemie
AU2001237518A1 (en) Polyfluoroalkylimidazole derivatives, their preparation and therapeutic application

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BG BR CA CN CZ EE GE HR HU ID IL IN JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA US VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BG BR CA CN CZ EE GE HR HU ID IL IN JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA US VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2000925239

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000925239

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10018437

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000925239

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载